Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract.
• Metastatic GISTs present significant clinical management challenges due to poor prognosis.
• Tyrosine kinase inhibitors (TKIs) like imatinib and sunitinib are standard treatments.

Observation:

• A 57-year-old male patient with metastatic GISTs progressed despite first-line imatinib and second-line sunitinib therapy.
• The patient received apatinib, a multi-target tyrosine kinase inhibitor, after failure of prior treatments.
• Clinical benefit was observed, with stable disease achieved on apatinib.

Findings:

• The patient achieved a progression-free survival of at least 8 months on apatinib.
• Apatinib demonstrated efficacy in a patient with metastatic GISTs refractory to imatinib and sunitinib.
• Reported toxicities, including hypertension and proteinuria, were manageable and well-tolerated.

Implications:

• Apatinib represents a potential therapeutic option for patients with advanced GISTs who have exhausted other TKI treatments.
• This case highlights the role of apatinib in refractory GISTs, suggesting its value in personalized cancer therapy.
• Further investigation into apatinib's efficacy and safety in a broader GISTs population is warranted.